Peptide access may soon broaden in the US as the FDA's final decision could legitimize peptide compounding, giving telehealth brands with compounding facilities a head start.
Consumers embrace ChatGPT for health questions, but may remain reluctant to connect sensitive health data with AI tools.
AI is fueling pre-appointment research, forcing doctors to validate information and pharma to maintain accurate and discoverable online content.
Cyclospora cases tied to fresh produce are mounting amid low confidence in the FDA and food safety, raising the value of transparent updates.
Smartphone access and QR sharing could ease fragmented care if people embrace it, but widespread adoption is far from guaranteed.
Trump's tariff reversal targets generic drugs, leaving low-margin manufacturers with few options beyond raising prices or exiting the US market.
Marketers are following the trend, as fiber emerges as a front-of-package selling point for supplement and food brands.
On today’s podcast, we go beyond the headlines to explore what’s driving the latest wave of GLP-1 momentum, why this represents a lasting shift rather than just another healthcare trend, the biggest misconception retailers still have about how these drugs are changing consumer behavior, and which parts of the retail playbook need to be rewritten as consumers change how they eat, shop, and live. Tune in for a discussion featuring Vice President of Content and host Suzy Davidkhanian, along with Senior Analysts Rajiv Leventhal and Rachel Wolff.
OpenAI's latest ChatGPT health advice lawsuit could force stronger AI medical guardrails.
Novo's GLP-1 ad lawsuit against Lilly could redefine the standards for comparative drug advertising in a market projected to reach $200 billion.
Its no-subscription Cirqa band joins a crowded field where AI features, not screens, set products apart.
With no confirmed source for the cyclospora outbreak, clear communication may be key to winning diners back.
Pharma marketers should match the influence of clinical proof, cost details, and patient voices to the values of each audience.
The next phase of GLP-1 marketing competition may hinge on whether brands convince consumers to stay on treatment or build habits that last after stopping them.
Affordability drives food purchases more than health, but brands that pair value with nutrition stand to gain.
Reaching patients through insurers and providers could unlock wearable adoption among higher-need cohorts and strengthen long-term loyalty.
Younger adults mostly use these health features, but older adults' faster uptake points to untapped demand.
Its acquisition of a psychedelic drug developer adds credibility to the field, but commercialization will hinge on reimbursement and supervised care.
The decline mostly reflects pullbacks in diabetes and blood disorder advertising, not a broad retreat from linear TV advertising.
Healthcare providers and marketers in the UK should help teens build healthier habits ahead of social media bans and curfews.